CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishHypertrophic cardiomyopathy is a complex and relatively common genetic cardiac disorder (about 1:500 in the general adult population)1that has been the subject of intense scrutiny and investigation for over 40 years. his clinical scientific statement represents the consensus of a panel of experts appointed by the ACC and ESC. The writing group is comprised of cardiovascular specialists and molecular biologists, each havingextensive experience with HCM. The panel focused largely on the management of this complex disease and derived prudent, practical, and contemporary treatment strategies for the many subgroups of patients comprising the broad HCM disease spectrum.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American college of cardiology/european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the american college of cardiology foundation task force on clinical expert consensus documents and the european society of cardiology committee for practice guidelines |
| Autori: | |
| Data di pubblicazione: | 2003 |
| Rivista: | |
| Citazione: | Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American college of cardiology/european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the american college of cardiology foundation task force on clinical expert consensus documents and the european society of cardiology committee for practice guidelines / Maron, Bj; Mckenna, Wj; Danielson, Gk; Kappenberger, Lj; Kuhn, Hj; Seidman, Ce; Shah, Pm; Spencer WH, 3rd; Spirito, P; Ten Cate, Fj; Wigle, Ed; Vogel, Ra; Abrams, J; Bates, Er; Brodie, Br; Danias, Pg; Gregoratos, G; Hlatky, Ma; Hochman, Js; Kaul, S; Lichtenberg, Rc; Lindner, Jr; O'Rourke, Ra; Pohost, Gm; Schofield, Rs; Tracy, Cm; Winters WL, Jr; Klein, Ww; Priori, SILVIA GIULIANA; Alonso Garcia, A; Blomstrom Lundqvist, C; De Backer, G; Deckers, J; Flather, M; Hradec, J; Oto, A; Parkhomenko, A; Silber, S; Torbicki, A.. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 0735-1097. - STAMPA. - 42(2003), pp. 1687-1713. |
| Abstract: | Hypertrophic cardiomyopathy is a complex and relatively common genetic cardiac disorder (about 1:500 in the general adult population)1that has been the subject of intense scrutiny and investigation for over 40 years. his clinical scientific statement represents the consensus of a panel of experts appointed by the ACC and ESC. The writing group is comprised of cardiovascular specialists and molecular biologists, each havingextensive experience with HCM. The panel focused largely on the management of this complex disease and derived prudent, practical, and contemporary treatment strategies for the many subgroups of patients comprising the broad HCM disease spectrum. |
| Handle: | http://hdl.handle.net/11571/18103 |
| Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
Copyright © 2018